The FDA and Aventis Pharmaceuticals recently revised the prescribing information for the enoxaparin sodium injection (Lovenox). The new label provides additional information on pharmacokinetics, precautions, and dosage and administration for obese and low-weight patients, as well as for those with severe renal impairment. Also, it now displays a table that clearly sets out the recommended prophylaxis and treatment dosage regimens for patients with severe renal impairment.

A dosage adjustment is now recommended for patients with severe renal impairment (creatinine clearance < 30 mL/min) who have increased exposure to enoxaparin. Patients with mild or moderate renal impairment do not require a specific dosage adjustment.